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To compare health, educational and employment outcomes of schoolchildren receiving
medication for a skin disorder with peers.
Methods
This retrospective population cohort study linked eight Scotland-wide databases, covering
dispensed prescriptions, hospital admissions, maternity records, death certificates, annual
pupil census, school examinations, school absences/exclusions and unemployment to
investigate educational (absence, exclusion, special educational need, academic attain-
ment), employment, and health (admissions and mortality) outcomes of 766,244 children
attending local authority run primary, secondary and special schools in Scotland between
2009 and 2013.
Results
After adjusting for sociodemographic and maternity confounders the 130,087 (17.0%) chil-
dren treated for a skin disorder had increased hospitalisation, particularly within one year of
commencing treatment (IRR 1.38, 95% CI 1.35–1.41, p<0.001) and mortality (HR 1.50, 95%
CI 1.18–1.90, p<0.001). They had greater special educational need (OR 1.19, 95% CI 1.17–
1.21, p<0.001) and more frequent absences from school (IRR 1.07, 95% CI 1.06–1.08,
p<0.001) but did not exhibit poorer exam attainment or increased post-school unemployment.
The associations remained after further adjustment for comorbid chronic conditions.
Conclusions
Despite increased hospitalisation, school absenteeism, and special educational need, chil-
dren treated for a skin disorder did not have poorer exam attainment or employment
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outcomes. Whilst findings relating to educational and employment outcomes are reassuring,
the association with increased risk of mortality is alarming and merits further investigation.
Background
Skin disorders including psoriasis and eczema, also referred to as atopic dermatitis, are the
fourth leading cause of disability worldwide [1]. These disorders have an impact on quality of
life [2–6] and create a burden on healthcare resources [4–6]. The annual cost of eczema and
psoriasis in the USA have been estimated at $5.3billion [7] and as much as $63.2billion [8]
respectively and it has been reported that skin diseases globally contributed 1.8% (18th leading
contributor) and 1.4% (22nd leading contributor) to disability-adjusted life years (DALYs) in
2013 and 2016 respectively; eczema and psoriasis contributing 0.4% and 0.2% respectively in
the former report [1,9]. Skin disorders are more common in children than adults. Worldwide,
the prevalence of eczema has been reported as 17–20% in children compared with 1–3% in
adults [10,11]. Childhood prevalence varies greatly between countries [12,13], ranging from
0.2% in China to 24.6% in Columbia. Psoriasis is a less common condition in children but still
affects around 0.5% [14]. Children who have a skin disorder often suffer from additional medi-
cal conditions. Studies have reported increased risk of asthma, allergic rhinitis, hay fever and
autoimmune disorders among children with eczema [15–18] and a higher prevalence of obesity,
diabetes, cardiovascular disorders, rheumatoid arthritis, and Crohn’s disease among children
with psoriasis [14,19–21]. Eczema and psoriasis have also been linked with a number of psychi-
atric disorders and mental health problems including depression and anxiety [22–28]. In addi-
tion to depression, childhood eczema has been associated with comorbid attention deficit
hyperactivity disorder (ADHD) [29–31] and suicidal ideation/behaviour [32–34]. Adults with
skin disorders reportedly suffer from increased mortality [35,36] and, whilst studies investigat-
ing hospitalisation and mortality in children and adolescents are rare, increased psychiatric hos-
pitalisation [37] and mortality [38] among children with psoriasis have been reported.
Given that these disorders not only impact on physical and mental health but also affect
sleep and daily function [39], it is plausible that having a skin disorder may adversely affect
educational attainment and employment. Increased absence from school and work [39] and
perceived school difficulty among students [40] have been reported, however a recent system-
atic review of educational and employment outcomes among children with eczema identified
only one eligible study [41]. The study reported no association between eczema and perfor-
mance in a secondary school entrance exam undertaken at 11years of age but did not have
information on subsequent school academic attainment or employment after leaving school
[42]. A subsequent national study across Sweden found no associations between atopic derma-
titis and lower cognitive function or lower academic attainment but did not investigate other
educational or health outcomes. Further, it only studied men aged 17–20 between 1969 and
1976 who possibly had more severe atopic dermatitis, limiting generalizability [43]. This study
addresses a significant gap in the literature by investigating school attendance, educational
attainment, and employment, as well as hospitalisations and mortality, in a single unselected
country-wide cohort of schoolchildren treated for a skin disorder compared to their peers.
Methods
Databases
We linked Scotland-wide, individual-level data from four health databases, held by Public
Health Scotland, and four education databases, held by the Scottish Exchange of Educational
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Data (ScotXed). The linkage methodology has been described previously [44–50]. The Pre-
scribing Information System (PIS) collects information on all prescriptions dispensed to Scot-
tish residents by community pharmacies or primary care. The Scottish Morbidity Record
(SMR) 02 maternity database collects data on maternal, obstetric and child factors. SMR 01
and SMR 04 record acute and psychiatric hospital admissions, including dates of admission
and discharge and International Classification of Diseases (ICD-10) diagnostic codes. The
National Records of Scotland collect data from death certificates, including date and cause of
death.
The pupil census is conducted annually by all local authority run primary, secondary and
special schools across Scotland and includes whether a child has a special educational need
and its type. Absences and exclusions are collected prospectively and appended at the end of
the school year. The Scottish Qualifications Authority collects examination attainment data
for all Scottish schoolchildren. The school leaver database collects information on pupils six
months after leaving school: paid/voluntary employment, higher/further education, training
or unemployment.
Inclusion criteria, definitions and outcomes
Our cohort comprised school pupils included in the annual school censuses undertaken
between 2009 and 2013 inclusive. The mean number of observed school years per pupil was
3.65 (range 1–5 years). We excluded school records where age was recorded as<4 years or
>19 years. For multiple births involving offspring of the same sex, it is not possible to be cer-
tain that the correct child has been linked; therefore, inclusion was restricted to singleton chil-
dren. In the absence of primary care data or a national diagnostic database to identify patients
we used PIS data to ascertain children treated for a skin disorder defined as: receipt of one or
more prescriptions per year for an emollient (British National Formulary (BNF) section
13.2.1), topical corticosteroid (BNF section 13.4), or preparations for eczema or psoriasis (BNF
section 13.5). Children who did not receive any of these drugs were included in the peer
group.
We studied five educational outcomes: (i) annual number of days absent, (ii) annual num-
ber of school exclusions for challenging/disruptive behaviour, (iii) annual record of special
educational need, (iv) attainment in national examinations, and (v) unemployment after leav-
ing school. The latter two outcomes were restricted to pupils who left school during the study
period. Absence and exclusion data were only available for years 2009, 2010 and 2012. Special
educational need is defined as being unable to benefit from school education without help
beyond that normally given to schoolchildren of the same age. We included special educational
need attributed to intellectual disabilities, learning difficulties, dyslexia, language or speech dis-
order, physical, motor or sensory impairment, autistic spectrum disorder, social, emotional
and behavioural difficulties, physical health conditions, and mental health conditions. Chil-
dren could have more than one type recorded. Academic achievement was derived using the
total number of awards attained at each level of the Scottish Credit Qualifications Framework
(SCQF) [51] and converted into an ordinal variable: low, basic, broad/general and high attain-
ment. Destination six months after leaving school was collapsed into a dichotomous variable
of education/employment/training or unemployment. We studied two health outcomes: all-
cause hospital admission and all-cause mortality. Data on hospital admissions and deaths were
available until September 2014; providing a mean follow-up period of 4.3 years (maximum 5
years).
We adjusted for several confounders. The pupil census provided children’s sex, age and eth-
nicity. Area socioeconomic deprivation was derived from postcode of residence using the
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Scottish Index of Multiple Deprivation (SIMD) 2012, and children were allocated to general
population quintiles. SIMD is derived from 38 indicators across 7 domains (income, employ-
ment, health, housing, geographic access, crime and education, skills and training) using infor-
mation collected by datazone of residence (median population 769). Retrospective linkage to
SMR 02 provided maternal age at delivery, parity, maternal smoking, gestation at delivery,
mode of delivery and 5-minute Apgar score. We derived sex-, gestation-specific birthweight
centiles as a measure of intra-uterine growth. We have previously demonstrated that chronic
conditions such as ADHD [45,46], epilepsy [45,47], diabetes [45,48], asthma [45,49], and
depression [45,50] are independently associated with poorer educational outcomes and health
outcomes. Therefore, to enable adjustment for these comorbid conditions, we used PIS data to
identify children dispensed medication for diabetes (insulin), epilepsy (any drug from BNF
section 4.8), ADHD (methylphenidate hydrochloride, dexamphetamine sulphate, atomoxetine
or lisdexamfetamine dimesylate), or depression (tricyclic antidepressant, selective serotonin
reuptake inhibitor, mirtazapine or venlafaxine) on at least one occasion over the school year
and those dispensed medication for asthma (inhaled corticosteroid plus beta agonist) twice or
more over one year.
Statistical analyses
The characteristics of children treated for a skin disorder were compared with their peers
using chi square tests for categorical data, and chi square tests for trend for ordinal data. Spe-
cial educational need, absences and exclusions, recorded annually, were analysed as yearly out-
comes using population-averaged generalised estimating equations (GEEs) [52] which adjust
for correlations between observations relating to the same pupil across different census years.
We used the user-written quasi-likelihood under the independence model criterion (QIC) sta-
tistic to compare different correlation structures. The structure with the lowest trace QIC was
selected as most appropriate [53]. Number of days absent and number of school exclusions
were modelled using longitudinal GEE analyses with a negative binomial distribution and log
link function. Number of possible annual attendances was used as an offset variable to adjust
for individual exposure time. Special educational need was modelled using GEE analyses with
a binomial distribution and logit link. Logistic regression (generalised ordinal and binary) was
used to model exam attainment and unemployment respectively whilst hospitalisation and
mortality were modelled using Cox proportional hazard models. In the Cox models, children
prescribed relevant skin disorder medication were followed from the date of their first pre-
scription. Children who did not receive medication for a skin disorder were followed from the
date of their first school census year. The proportional hazards assumption was tested formally
using the estat phtest command within Stata and, where the assumption did not hold, Poisson
piecewise regression models were used. Multivariable models were run univariately then
adjusted for sociodemographic and maternity confounders. We also explored age, sex and
deprivation as potential effect modifiers. We tested for statistical interactions and undertook
sub-group analyses where these were significant at P<0.05.
Finally, to test for confounding due to comorbid conditions, we re-ran the models for all of
the main outcomes adjusting for the presence of diabetes, asthma, epilepsy, ADHD and
depression, in turn, before including all in the model. All statistical analyses were undertaken
using Stata MP version 14.1
Approvals
The study was approved by the NHS Scotland Public Benefit and Privacy Panel. A data pro-
cessing agreement was drafted between Glasgow University and Public Health Scotland and a
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data sharing agreement between Glasgow University and ScotXed. The linked data extract was
anonymised, then stored and analysed within the national safe haven.
The role of the funding source
The sponsor and funders had no role in the design and conduct of the study; collection, man-
agement, analysis, and interpretation of the data; preparation, review or approval of the manu-
script, or decision to submit the manuscript for publication.
Results
Between 2009 and 2013, 766,244 singleton children attended Scottish schools. Overall, 130,087
(17.0%) children were treated for a skin disorder (Table 1). Children treated for a skin disorder
were more likely to be female and Asian, and less likely to live in deprived areas. They were
more likely to have required assisted or operative delivery and had lower five-minute Apgar
scores. Their mothers were older, less likely to have smoked during pregnancy and were more
likely to have been nulliparous. Compared to their peers, children treated for a skin disorder
were also more likely to be on medication for diabetes (0.5% versus 0.4% of peers, p = 0.006),
asthma (11.8% versus 4.8% of peers, p<0.001), epilepsy (1.0% versus 0.6% of peers, p<0.001),
ADHD (1.0% versus 0.9% of peers, p = 0.007) and depression (1.0% versus 0.6% of peers,
p<0.001) (Table 1).
Analyses of school absences and exclusions were conducted on 702,210 children. Children
treated for a skin disorder had more days absent from school than their peers after adjusting
for sociodemographic and maternity factors (IRR 1.07, 95% CI 1.06–1.08, p<0.001). There
was an interaction with age (p<0.001) whereby the association between skin disorder and
absenteeism was stronger among children aged 11–14 years (IRR 1.09, 95% CI 1.07–1.11,
p<0.001) compared to children older than 14 years (IRR 1.03, 95% CI 1.01–1.04, p<0.001)
and younger than 11 years (IRR 1.07, 95% CI 1.06–1.08, p<0.001).
Treated skin disorders were associated with lower rates of school exclusion after adjusting
for sociodemographic and maternity confounders (IRR 0.91, 95% CI 0.85–0.97, p = 0.004).
However, on subgroup analyses, this association only reached statistical significance among
boys (IRR 0.91, 95% CI 0.84–0.98, p = 0.015), and children aged >14 years (IRR 0.86, 95% CI
0.78–0.94, p = 0.001).
Children treated for a skin disorder were more likely to have a record of special educational
need after adjusting for sociodemographic and maternity factors (OR 1.19, 95% CI 1.17–1.21,
p<0.001). There was an interaction with age (p<0.001) whereby the association was stronger
among children older than 14 years of age (OR 1.28, 95% CI 1.23–1.32, p<0.001) compared to
children aged 11–14 years (OR 1.23, 95% CI 1.19–1.27, p<0.001) and children younger than
11 years (OR 1.13, 95% CI 1.10–1.16, p<0.001).
Among the 139,205 children who had undertaken exams, there was no significant associa-
tion between treatment for a skin disorder and academic attainment after adjustment for
sociodemographic and maternity factors (OR 1.01, 95% CI 0.96–1.05, p = 0.735). Among the
217,924 children who left school during the study period, 3,917 (25.5%) of those treated for a
skin disorder left school before 16 years of age compared with 58,864 (29.1%) of their peers
(p<0.001). Having a skin disorder was associated with lower risk of unemployment overall
after adjusting for sociodemographic and maternity factors (OR 0.90, 95% CI 0.85–0.96,
p<0.001). However, on subgroup analyses, this association was only statistically significant
among boys (IRR 0.86, 95% CI 0.79–0.94, p = 0.001), and children in the most deprived quin-
tile (IRR 0.83, 95% CI 0.74–0.92, p = 0.001).
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Table 1. Sociodemographic characteristics of schoolchildren by the presence of a treated Skin Disorder (SD).
No SD SD
N = 636,157 N = 130,087
N % N % P value
Sociodemographic factors
Sex
Male 328,975 51.7 61,315 47.1 <0.001 �
Female 307,182 48.3 68,772 52.9
Missing 0 0
Deprivation quintile
1 (most deprived) 145,343 22.9 28,699 22.1 <0.001 ��
2 127,911 20.1 25,721 19.8
3 122,767 19.3 25,065 19.3
4 123,784 19.5 25,575 19.7
5 (least deprived) 115,836 18.2 24,933 19.2
Missing 516 94
Ethnic group
White 605,003 95.1 119,811 92.1 <0.001 �
Asian 12,036 1.9 5,624 4.3
Black 1,222 0.2 682 0.5
Mixed 5,211 0.8 1,473 1.1
Other 1,691 0.3 396 0.3
Missing 10,994 2,101
Medication for comorbid conditions
Diabetes 2,705 0.4 625 0.5 0.006 �
Asthma 30,568 4.8 15,332 11.8 <0.001 �
Epilepsy 4,054 0.6 1,260 1.0 <0.001 �
ADHD 6,067 0.9 1,346 1.0 0.007 �
Depression 4,088 0.6 1,254 1.0 <0.001 �
Maternity factors
Maternal age (years)
�24 176,254 27.7 33,624 25.8 <0.001 ��
25–29 186,894 29.4 37,646 28.9
30–34 178,753 28.1 38,182 29.4
�35 94,244 14.8 20,635 15.9
Missing 12 0
Maternal smoking
No 403,035 63.4 88,079 67.7 <0.001 �
Yes 159,477 25.1 28,312 21.8
Missing 0 0
Parity
0 282,925 44.7 62,740 48.5 <0.001 ��
1 220,095 34.8 44,047 34.1
>1 130,120 20.6 22,450 17.4
Missing 3,017 850
Mode of delivery
SVD 431,855 67.9 84,364 64.9 <0.001 �
Assisted vaginal 74,596 11.7 17,061 13.1
Breech vaginal 1,895 0.3 338 0.3
(Continued)
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Linkage to hospital records provided 2.84 million person years of follow-up. The mean fol-
low-up duration was 3.7 years. Of the 766,244 children, 153,002 were admitted to hospital at
least once and 294,864 hospital admissions occurred in total. In the Cox proportional hazards
models, children treated for a skin disorder experienced increased risk of hospitalisation for
any cause (HR 1.29, 95% CI 1.27–1.30, p<0.001). However, the proportionality assumption
was not met (p<0.001). On running a Poisson piecewise regression model, children treated for
a skin disorder were more likely to be hospitalised over all five study years and across all ages.
Table 1. (Continued)
No SD SD
N = 636,157 N = 130,087
N % N % P value
Elective CS 48,170 7.6 10,144 7.8
Emergency CS 79,500 12.5 18,156 14.0
Other 139 0.0 24 0.0
Missing 2 0
Gestation (weeks)
<24 27 0.0 2 0.0 0.547 ��
24–27 944 0.1 181 0.1
28–32 5,880 0.9 1,178 0.9
33–36 29,471 4.6 6,131 4.7
37 31,315 4.9 6,304 4.8
38 79,519 12.5 16,473 12.7
39 131,617 20.7 27,123 20.9
40 191,706 30.2 38,724 29.8
41 141,803 22.3 29,390 22.6
42 22,741 3.6 4,383 3.4
43 523 0.1 107 0.1
>43 115 0.0 25 0.0
Missing 496 66
Sex-gestation-specific birthweight centile
1–3 26,182 4.1 5,304 4.1 0.992 ��
4–10 56,999 9.0 11,647 9.0
11–20 75,639 11.9 15,709 12.1
21–80 373,841 58.8 76,280 58.7
81–90 54,248 8.5 11,115 8.6
91–97 34,274 5.4 6,947 5.3
98–100 14,131 2.2 2,948 2.3
Missing 843 137
5-minute Apgar score
1–3 3,162 0.5 547 0.4 <0.001 ��
4–6 6,094 1.0 1,208 0.9
7–10 620,650 98.5 126,762 98.6
Missing 6,251 1,570
SD Skin Disorder; N number; ADHD Attention Deficit Hyperactivity Disorder
SVD spontaneous vaginal delivery; CS Caesarean section
� chi2 test for association;
�� chi2 test for trend
https://doi.org/10.1371/journal.pone.0243383.t001
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However, the incidence rate ratio was highest in the first recorded year of treatment (IRR 1.38,
95% CI 1.35–1.41, p<0.001) and fell over the remaining four years. It also peaked among chil-
dren aged 11–12 years (IRR 1.40, 95% CI 1.35–1.46, p<0.001) on stratifying the analyses by
age at admission (<6, 7–8, 9–10, 11–12, 13–14, 15–16,>17 years). There was an interaction
with sex (p<0.001) whereby the association between a treated skin disorder and hospital
admission was present in both boys and girls but stronger in the former. Fig 1A and 1B show
fully adjusted incidence rate ratios, stratified by sex, for all-cause hospitalisation for each year
of follow-up and by age at admission derived from Poisson piecewise regression models.
There were 491 deaths over the follow up period; 87 among children treated for a skin dis-
order and 404 among their peers. Children treated for a skin disorder were more likely to die
from any cause over follow-up after adjusting for sociodemographic and maternity factors
(HR 1.50, 95% CI 1.18–1.90, p<0.001). Among all children who died, the three most com-
monly recorded causes of death were external causes (37.5%), neoplasms (17.8%) and diseases
of the nervous system (10.4%). External causes accounted for a smaller proportion of deaths
among children treated for skin disorders than their peers (20.7% versus 41.1%) as did neo-
plasms (13.8% versus 17.8%). In contrast, children treated for a skin disorder were more likely
to have their cause of death attributed to diseases of the nervous system (14.9% versus 9.4%).
Adjusting the main analyses for presence of comorbid conditions, both individually and
then together, did not alter the findings (Table 2). After adjusting for all of the comorbid con-
ditions, children treated for a skin disorder still had increased risk of absenteeism (IRR 1.05,
95% CI 1.04–1.05, p<0.001), special educational need (OR 1.14, 95% CI 1.12–1.16, p<0.001),
hospitalisation (HR 1.22, 95% CI 1.22–1.24, p<0.001), and mortality (HR 1.31, 95% CI 1.03–
1.67, p = 0.027), but decreased risk of school exclusion (IRR 0.91, 95% CI 0.86–0.97, p = 0.006)
and unemployment (OR 0.89, 95% CI 0.84–0.95, p<0.001). There remained no association
with academic attainment (OR 0.99, 95% CI 0.95–1.04, p = 0.762). Confirmation of these
results will require further research, identifying patients by their diagnosis and recording the
clinical severity of their condition.
Discussion
This study is unique in identifying a large cohort of children from across Scotland who have
received topical treatment for a skin problem. The absence of primary care data or a national
database for outpatient diagnoses is a limitation and complicates the process of patient identi-
fication and deduction of type and severity of disorder. Nevertheless, in identifying patients by
community prescriptions of topical treatment, this study found that, compared to peers, chil-
dren treated for a skin disorder were more likely to be hospitalised, had more absences from
school, were more likely to also be on medication for asthma, diabetes, epilepsy, depression
and ADHD, and were more likely to be recorded as having special educational need. However,
there was no evidence that this resulted in a longer-term adverse impact on attainment, which
concurs with previous studies on atopic dermatitis [42,43], and employment. These latter find-
ings may provide reassurance to affected children and their parents.
Whilst the findings relating to educational and employment outcomes were reassuring, we
did demonstrate that, even after adjusting for comorbid conditions, children treated for a skin
disorder were at increased risk of all-cause mortality. It is possible however, that patients with
terminal disease, disease that results in immobility, or disease treatment that can result in skin
side effects, may be prescribed emollients and steroids in the community for rashes that do not
correspond to the innate, chronic skin disease that we would want to study. In any observa-
tional study, residual confounding and reverse causation are possible. Therefore, these findings
require corroboration in other studies and if replicated merit further investigation. In
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particular, our findings that children with a skin disorder had less risk of exclusion, albeit only
statistically significant among boys and those older than 14years of age, and less risk of unem-
ployment, albeit only statistically significant among boys and those in the most deprived quin-
tile, were unexpected and may be due to residual confounders. Therefore, these results should
be corroborated and investigated further in future studies.
Previous studies investigating health outcomes of children with skin disorders are limited in
number. Whilst adults with skin disorders reportedly suffer from increased mortality [35,36],
studies reporting hospitalisation and mortality among children and adolescents are rare [37,38].
However, our finding of increased risk of death does concur with a previous study reporting
greater premature mortality among children with psoriasis [38]. Our findings of increased spe-
cial educational need and treatment for asthma, diabetes, epilepsy, depression and ADHD con-
cur partially with previous studies which have reported greater risk of asthma [15,16,18] and
ADHD [29–31] among children with eczema, increased incidence of diabetes [14,19,21] among
children with psoriasis, and more psychiatric disorders and mental health problems among
both including specifically depression and anxiety [22–28]. We have previously reported that
children treated for diabetes, asthma, epilepsy, ADHD, and depression have poorer educational
and health outcomes, including hospitalisation and mortality, compared to peers, and therefore
adjusted for these conditions in our analyses [45–50]. However wider comorbidities exist which
we could not adjust for. For example, childhood eczema has also been associated with comorbid
allergic rhinitis, hay fever and autoimmune disorders [15–17] and even suicidal ideation/behav-
iour [32–34] whilst psoriasis has been associated with obesity, cardiovascular disorders, rheu-
matoid arthritis, and Crohn’s disease [14,19–21] as well as more psychiatric hospitalisations
[37]. Therefore, in addition to the direct physical and mental effects associated with skin disor-
ders, it is possible that the greater hospitalisation and mortality observed may be partly attribut-
able to the increased physical and mental comorbidities associated with both eczema and
psoriasis over and above those adjusted for in our analyses.
Fig 1. Association between treatment for a skin disorder and all-cause hospitalisation by sex (boys = solid square; girls = hollow
diamond). a. By time from commencement of medication. b. By age at admission. Adjusted for age, sex, deprivation quintile, ethnic
group, maternal age, maternal smoking, parity, mode of delivery, gestation at delivery, sex- gestation-specific birthweight centile and
5-minute Apgar score. SIMD–Scottish Index of Multiple Deprivation.
https://doi.org/10.1371/journal.pone.0243383.g001
Table 2. Educational and health outcomes additionally adjusted for comorbid chronic conditions.
Absence Exclusion SEN Attainment Unemployment Admission Mortality
IRR 95% CI IRR 95% CI OR 95% CI OR 95% CI OR 95% CI HR 95% CI HR 95% CI
univariate 0.99 0.98–1.00 0.67 0.63–0.72 1.07 1.05–1.09 0.84 0.81–0.87 0.81 0.76–0.86 1.26 1.24–1.28 1.45 1.15–1.83
Multivariate 1 � 1.04 1.03–1.05 0.83 0.78–0.89 1.14 1.12–1.16 0.98 0.94–1.02 0.89 0.84–0.94 1.27 1.25–1.29 1.48 1.17–1.87
Multivariate 2 �� 1.07 1.06–1.08 0.91 0.85–0.97 1.19 1.17–1.21 1.01 0.96–1.05 0.90 0.85–0.96 1.29 1.27–1.30 1.50 1.18–1.90
Multivariate 2 also adjusted for diabetes 1.07 1.06–1.08 0.91 0.85–0.97 1.19 1.17–1.21 1.01 0.96–1.05 0.90 0.85–0.96 1.28 1.27–1.30 1.50 1.18–1.90
Multivariate 2 also adjusted for asthma 1.05 1.04–1.06 0.92 0.86–0.98 1.16 1.14–1.19 1.00 0.96–1.04 0.90 0.85–0.96 1.23 1.22–1.25 1.44 1.13–1.83
Multivariate 2 also adjusted for epilepsy 1.07 1.06–1.08 0.91 0.85–0.97 1.17 1.15–1.20 1.01 0.96–1.05 0.90 0.85–0.96 1.28 1.26–1.29 1.37 1.08–1.73
Multivariate 2 also adjusted for ADHD 1.07 1.06–1.08 0.90 0.85–0.96 1.19 1.16–1.21 1.01 0.96–1.05 0.90 0.85–0.96 1.29 1.27–1.30 1.50 1.18–1.90
Multivariate 2 also adjusted for depression 1.07 1.06–1.07 0.91 0.85–0.97 1.18 1.16–1.21 1.00 0.96–1.05 0.90 0.84–0.95 1.28 1.26–1.30 1.47 1.16–1.87
Multivariate 2 adjusted for all comorbid
conditions
1.05 1.04–1.05 0.91 0.86–0.97 1.14 1.12–1.16 0.99 0.95–1.04 0.89 0.84–0.95 1.22 1.20–1.24 1.31 1.03–1.67
�Adjusted for age, sex, deprivation quintile, ethnic group
�Also adjusted for maternal age, maternal smoking, parity, mode of delivery, gestation at delivery, sex- gestation-specific birthweight centile and 5-minute Apgar score
IRR Incidence Rate Ratio; OR Odds Ratio; HR Hazard Ratio; CI confidence interval; ADHD Attention Deficit Hyperactivity Disorder
https://doi.org/10.1371/journal.pone.0243383.t002
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Previous studies investigating educational outcomes of children with skin disorders are rarer
still and face methodological limitations. Indeed, a systematic review of educational and
employment outcomes among children with eczema identified only one eligible study [41].
General school difficulty among affected children has been reported previously [40] and reports
of increased absenteeism [39] yet unaffected attainment [42,43] concur with our own findings.
However, the latter studies on attainment were limited whereby one only investigated attain-
ment on entry to school at age 11 for children with eczema, rather than final attainment on leav-
ing school, and the other only investigated attainment among boys with severe atopic dermatitis
limiting generalisability. We have previously demonstrated that children treated for diabetes,
asthma, epilepsy ADHD, and depression have greater risk of absenteeism and special educa-
tional need compared to peers however our new findings pertaining to skin disorders remained
after adjusting for presence of those conditions [45–50]. In addition to the direct effects of hav-
ing a skin disorder, our findings of increased absenteeism and special educational need may
therefore similarly be partly attributable to the wider increase in physical and mental comorbid-
ities experienced by affected children which we could not adjust for as highlighted already.
Our study addressed a significant gap in the literature by investigating several health and
educational outcomes. Ours was a large, non-selective study including children attending
schools across the whole of Scotland. Because the sampling frame was mainstream and special
schools, rather than hospital clinics, ascertainment of children treated for a skin disorder was
not restricted to the most severe skin disorders and we were able to adjust for a wide range of
potential confounders: sociodemographic, maternity and comorbid conditions. The large
cohort provided sufficient power to test for statistical interactions and undertake sub-group
analyses where appropriate, and we were able to analyse a wide range of educational, employ-
ment and health outcomes within the same cohort of children.
Our study only included children attending local authority maintained schools; however, in
Scotland, less than 5% of children attend private schools. According to the 2011 Scottish Cen-
sus, 11% of Scottish residents aged 5–19 years were born outside of Scotland; consistent with
the 12% of Scottish children we could not link to Scottish maternity records. We used existing,
administrative databases established for other purposes. However, they undergo regular qual-
ity assurance checks. Linkage of education and health records relied on probabilistic matching
which has been validated to be 99% accurate for singletons [44].
Our findings require corroboration in other studies and if replicated merit further investi-
gation. Whilst acknowledging these uncertainties we conclude that, based on the observed
poorer health outcomes, the introduction of treatment plans is welcome as an attempt to pro-
vide children and adolescents who have skin disorders with more personalised healthcare.
Given that these children regularly experience comorbid physical and mental health condi-
tions, a more joined up approach to care is required. Indeed, in light of the common psycho-
logical burden of these conditions, a recent study highlighted unmet psychological and health
care needs of adolescents transitioning from paediatric to adult services and a requirement for
more dedicated dermatology clinics in the UK with embedded psychological support capable
of providing developmentally appropriate healthcare and psychosocial support for this popula-
tion [54]. Having observed poorer attendance and greater special educational need among
affected children we conclude that early identification and support should be a priority and
that interventions should focus on reducing the risk of school absenteeism. In order to reduce
school absenteeism or mitigate its effects, children treated for skin disorders should receive
integrated care from a multidisciplinary team covering physicians, teachers, parents, and
where mental health comorbidities exist, educational psychologists and social services as
appropriate. Their management should extend beyond healthcare to a programme of school-
based interventions.
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Conclusion
Children prescribed topical treatment for a skin disorder have an increased risk of hospitalisa-
tion and mortality, miss more days of school, have greater special educational need than peers,
and are more likely to be treated for other chronic conditions including diabetes, asthma, epi-
lepsy, ADHD and depression. However, there was no evidence of an adverse impact on lon-
ger-term educational outcomes in terms of poorer exam grades whilst at school and
unemployment after leaving school. Whilst our findings relating to educational and employ-
ment outcomes are reassuring, the association with increased risk of mortality is alarming and
merits further investigation. The introduction of treatment plans is welcome as an attempt to
provide children who have skin disorders with more personalised and joined-up healthcare.
School interventions should include measures aimed at reducing absenteeism and providing
support in the form of integrated care from a multidisciplinary team.
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